---
schema_version: "secwatch.filing_event.v1"
accession: "0001588978-23-000012"
form_type: "8-K"
ticker: "PRCT"
cik: "0001588978"
company_name: "PROCEPT BioRobotics Corp"
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:58:43.227158+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PROCEPT BioRobotics Q1 revenue up 72% to $24.4M; raises FY2023 revenue guidance to $128M

## Summary
- Total revenue $24.4M (+72% YoY); U.S. handpiece/consumables $11.8M (+165% YoY).
- Net loss $28.5M vs $17.2M; Adjusted EBITDA loss $23.9M vs $13.5M.
- FY2023 revenue guidance raised to $128M (from $125M); gross margin guidance ~54% (from ~53%).
- United Healthcare positive coverage policy effective June 1, 2023; national sales contract with largest U.S. IDN signed April 1.
- U.S. install base 192 AquaBeam systems; monthly utilization per account 6.3, up 14% YoY.

## SEC filing metadata
- accession: 0001588978-23-000012
- form_type: 8-K
- ticker: PRCT
- cik: 0001588978
- company_name: PROCEPT BioRobotics Corp
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1588978/000158897823000012/0001588978-23-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1588978/000158897823000012/prct-20230427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001588978-23-000012
- JSON: https://secwatch.observer/filing/0001588978-23-000012.json
- Plain text: https://secwatch.observer/filing/0001588978-23-000012.txt

## Key facts
- Earnings Releases
  PROCEPT BioRobotics Corp reported full year 2023 results: revenue $128 million. Guidance raised.
  - Period: full year 2023
  - Revenue: $128 million
  - Guidance: raised
  - Result: guidance update
  source text: The Company projects revenue for the full year 2023 to be $128 million, which represents 71% growth over the Company’s prior year revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1588978/000158897823000012/0001588978-23-000012-index.htm
- Earnings Releases
  PROCEPT BioRobotics Corp reported the quarter ended March 31, 2023 results: revenue Total revenue of $24.4 million for the first quarter of 2023, net income Net loss was $28.5 million for the first quarter of 2023.
  - Period: the quarter ended March 31, 2023
  - Revenue: Total revenue of $24.4 million for the first quarter of 2023
  - Net income: Net loss was $28.5 million for the first quarter of 2023
  - Result: reported results
  source text: PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1588978/000158897823000012/0001588978-23-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.